Related Experiment Video
Updated: Jul 8, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Matrix metalloproteinase inhibitors as anticancer agents
Panagiotis A Konstantinopoulos1, Michalis V Karamouzis, Athanasios G Papatsoris
1Department of Biological Chemistry, Medical School, University of Athens, 11527 Athens, Greece.
Abstract:
The important role of matrix metalloproteinases (MMPs) in the process of carcinogenesis is well established. However, despite very promising activity in a plethora of preclinical models, MMP inhibitors (MMPIs) failed to demonstrate a statistically significant survival advantage in advanced stage clinical trials in most human malignancies. Herein, we review the implication of MMPs in carcinogenesis, outline the pharmacology and current status of various MMPIs as anticancer agents and discuss the etiologies for the discrepancy between their preclinical and clinical evaluation. Finally, strategies for effective incorporation of MMPIs in current anticancer therapies are proposed.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Role of Matrix Metalloproteases in Degradation of ECM
A...
Drugs that Stabilize Microtubules
Mitogens and the Cell Cycle
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

